We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Unwanted Heparin Removed from Blood

By LabMedica International staff writers
Posted on 11 Nov 2008
A new approach for removing unwanted heparin from blood involves the use of microscopic beads of a polymer made from chitosan, a material obtained from shellfish. More...


Polymeric microspheres were obtained by the cross-linking of chitosan using genipin. In laboratory tests, the beads reduced concentrations of heparin to nearly zero within 10 minutes.

A main advantage of the polymeric system is that all of the basic reagents used to prepare the microspheres (chitosan, genipin, and surfactants) are inexpensive and nontoxic. The rate of heparin removal can be adjusted by changing the pH in a wide range. In order to enable heparin removal at higher pH values, cationically-modified chitosan microspheres resulted in a high rate of heparin removal, even at the pH value that is typical of blood (circa 7.4)--this enables even more medical applications of the polymer.

Doctors frequently need to remove heparin from the blood of patients who have undergone surgery or other procedures immediately after completing the procedure. If this is not done the heparin alone could lead to unwanted bleeding. Currently patients are given protamine, a drug that stops heparin's anticoagulant effects. However, protamine itself can cause serious adverse effects

The new polymer material was described by Krzysztof Szczubialka Ph.D., from the Jagiellonian University (Krakow, Poland), and colleagues in the December 8, 2008 issue of the American Chemical Society journal Biomacromolecules.

Related Links:
Jagiellonian University




New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.